# US 2021/0239680 A1 · Diagnosis and treatment of invasive aspergillosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239680 A1
- Document ID: US20210239680A1
- Status: Published application
- Kind: A1
- Application number: 17/069,641
- Filed: 2020-10-13
- Published: 2021-08-05
- Earliest claimed: 2012-09-07
- Assignees: The Brigham and Women's Hospital, Inc.; The Charles Stark Draper Laboratory, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.; The Charles Stark Draper Laboratory, Inc.
- Inventors: Sophia Koo; Horatio R. Thomas; James Constantine Comolli; Preshious Rearden; Lindsey R. Baden; Francisco M. Marty
- Web page: https://patentgrep.com/patent/US20210239680A1

## CPC

- G01N 33/497: of gaseous biological material, e.g. breath
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61P 31/10: Antimycotics
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 33/56961: {Plant cells or fungi}
- G01N 33/4977: {Metabolic gas from microbes, cell cultures or plant tissues}
- G01N 2333/38: from Aspergillus
- G01N 2500/10: involving cells
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for diagnosing, treating, and monitoring the treatment of invasive aspergillosis (IA) are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having IA.

## Claims

### Claim 1

A method for treating a subject with invasive aspergillosis (IA), the method comprising:
obtaining a sample from a subject;
detecting the presence in the sample of one, two, three, or more volatile organic compounds (VOCs) produced by the Aspergillus species in a sample, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene; and
administering a treatment to a subject when there are one, two, three or more of the VOCs present in the sample.

### Claim 2 (depends on 1)

The method of claim 1, comprising:
detecting the presence in the sample of one, two or three VOCs selected from the group consisting of farnesene, beta-vatirenene and cis-geranylacetone; and
administering the treatment to a subject when there are one, two or all three of farnesene, beta-vatirenene and cis-geranylacetone in the sample.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment comprises administration of one or more doses of one or more antifungal compounds.

### Claim 5 (depends on 1)

The method of claim 1, wherein:
the presence of one, two, three, or more of camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, or farnesene in the sample indicates the presence of an A. fumigatus infection in the subject;
the presence of one, two, three, or more of elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, and 1,5,9-trimethyl cyclododecatriene in the sample indicates the presence of an A. terreus infection in the subject; and
the presence of one or both of 9-decene-2-one and beta-sesquiphellandrene in the sample indicates the presence of an A. calidoustus infection in the subject.

### Claim 6 (depends on 5)

The method of claim 5, wherein:
administering the treatment to the subject having an A. fumigatus or A. terreus infection comprises administering an azole antifungal compound; or
administering the treatment to the subject having an A. calidoustus infection comprises administering an amphotericin B formulation.

### Claim 7

A method of monitoring efficacy of a treatment for invasive aspergillosis (IA) in a subject, the method comprising:
determining a first level of one, two, three, or more volatile organic compounds (VOCs) produced by the Aspergillus species in a sample comprising breath from the subject or headspace from a culture suspected of comprising Aspergillus isolated from the subject, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene, in the subject;
administering a treatment for IA to the subject;
determining a second level of the VOCs in a sample obtained after administration of the treatment to the subject; and
comparing the first and second levels of VOCs, wherein a decrease in the VOCs indicates that the treatment has been effective in treating the IA in the subject, and an increase or no change indicates that the treatment has not been effective in treating the IA in the subject.

### Claim 8 (depends on 7)

The method of claim 7, wherein the treatment comprises administration of one or more doses of one or more antifungal compounds.

### Claim 9

A method of identifying a candidate compound for the treatment of IA, the method comprising:
providing a test culture comprising one or more Aspergillus species;
detecting a baseline level of fungal volatile organic compounds (VOCs) in the headspace of the culture in the absence of the test compound, wherein the VOCs are selected from the group consisting of farnesene, beta-vatirenene, cis-geranylacetone, camphene, alpha-pinene, beta-pinene, limonene, alpha-bergamotene, farnesene, elixene, alpha-santalene, beta-elemene, acoradien, chamigrene, 1,5,9-trimethyl cyclododecatriene, 9-decene-2-one and beta-sesquiphellandrene;
contacting the test culture with a test compound;
determining a second level of the VOCs in a the test culture;
comparing the second level of VOCs to the baseline level; and
identifying a test compound that decreases levels of fungal VOCs in the test culture as a candidate compound for the treatment of IA.

### Claim at position 10

10-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein detecting the presence in the sample of one, two, three, or more VOCs comprises using a gas chromatography (GC) or spectrometry method.

### Claim 13 (depends on 12)

The method of claim 12, wherein the spectrophotometry method is mobility spectrometry (IMS) or differential mobility spectrometry (DMS).

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 16 (depends on 4)

The method of claim 4, wherein the antifungal compound is an amphotericin B formulation; an azole antifungal compound; or an echinocandin antifungal compound.

### Claim 17 (depends on 16)

The method of claim 16, wherein the amphotericin B formulation is deoxycholate amphotericin B or a lipid formulation of amphotericin B.

### Claim 18 (depends on 17)

The method of claim 17, wherein the lipid formulation of amphotericin B is selected from the group consisting of amphotericin B lipid complex (ABLC), liposomal amphotericin B (LAMB), and amphotericin B cholesteryl sulfate complex (AMB colloidal dispersion, ABCD).

### Claim 19 (depends on 16)

The method of claim 16, wherein the azole antifungal compound is selected from the group consisting of itraconazole (ITR), voriconazole (VOR), posaconazole (POS), ravuconazole (RAV), and isavuconazole (ISA).

### Claim 20 (depends on 16)

The method of claim 16, wherein the echinocandin antifungal compound is selected from the group consisting of caspofungin, micafungin and anidulafungin.

### Claim 21 (depends on 1)

The method of claim 1, wherein the sample is a liquid sample or a gas sample.

### Claim 22 (depends on 21)

The method of claim 21, wherein the liquid sample comprises culture media or bronchoalveolar washings.

### Claim 23 (depends on 21)

The method of claim 21, wherein the gas sample comprises breath of the subject or headspace from a culture isolated from the subject.

### Claim 24 (depends on 9)

The method of claim 9, wherein the test compound is selected from the group consisting of polypeptides, polynucleotides, and small molecules.
